1,513,644 Shares in Barinthus Biotherapeutics plc (NASDAQ:BRNS) Bought by Alphabet Inc.

Alphabet Inc. purchased a new stake in shares of Barinthus Biotherapeutics plc (NASDAQ:BRNS - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 1,513,644 shares of the company's stock, valued at approximately $2,119,000. Barinthus Biotherapeutics comprises about 0.1% of Alphabet Inc.'s investment portfolio, making the stock its 29th largest position. Alphabet Inc. owned about 3.88% of Barinthus Biotherapeutics at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in BRNS. DC Funds LP bought a new position in Barinthus Biotherapeutics during the 1st quarter valued at about $1,528,000. BlueCrest Capital Management Ltd acquired a new position in shares of Barinthus Biotherapeutics during the first quarter worth approximately $1,292,000. M&G Plc acquired a new position in shares of Barinthus Biotherapeutics during the second quarter worth approximately $7,276,000. Ipswich Investment Management Co. Inc. acquired a new position in shares of Barinthus Biotherapeutics during the second quarter worth approximately $32,000. Finally, Catalina Capital Group LLC acquired a new position in shares of Barinthus Biotherapeutics during the second quarter worth approximately $25,000. 25.20% of the stock is owned by institutional investors.

Barinthus Biotherapeutics Stock Performance

NASDAQ:BRNS traded up $0.03 during trading hours on Tuesday, hitting $1.34. The stock had a trading volume of 11,057 shares, compared to its average volume of 20,494. Barinthus Biotherapeutics plc has a one year low of $1.18 and a one year high of $5.10. The company has a market cap of $52.82 million, a price-to-earnings ratio of -0.74 and a beta of -0.53. The business's 50 day moving average is $1.39 and its 200-day moving average is $2.05.

Barinthus Biotherapeutics (NASDAQ:BRNS - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.01). On average, sell-side analysts anticipate that Barinthus Biotherapeutics plc will post -1.91 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. HC Wainwright reiterated a "buy" rating and set a $5.00 target price on shares of Barinthus Biotherapeutics in a research report on Monday, August 12th. Barclays cut their price objective on shares of Barinthus Biotherapeutics from $7.00 to $3.00 and set an "overweight" rating on the stock in a report on Thursday, June 13th. William Blair restated an "outperform" rating on shares of Barinthus Biotherapeutics in a report on Thursday, June 13th. Finally, Alliance Global Partners cut their price objective on shares of Barinthus Biotherapeutics from $11.00 to $9.50 and set a "buy" rating on the stock in a report on Tuesday, August 13th.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.